|
Ritodrine
resources
DRUG INFO
Ritodrine
Drug Name:
Ritodrine
|
|
|
Indication: For the treatment and prophylaxis of premature labour
Pharmacology: Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle.
Mechanism Of Action: Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions.
Drug Category: Adrenergic beta-Agonists; Tocolytic Agents; Sympathomimetic; ATC:G02CA01
Brand Names/Synonyms: BRN 2388728; DU-21220; RITODRINE; Ritodrina; Ritodrina [Inn-Spanish]; Ritodrine; Ritodrine Hcl; Ritodrine Hydrochloride; Ritodrine [Usan:Ban:Inn]; Ritodrinium; Ritodrinium [Inn-Latin]; Yutopar; Yutopar S.R
Dosage Forms: Solution for IV; Capsule (Extended-Release); Tablet; Intramuscular injection
Absorption: Not Available
Interactions: Interactions for Ritodrine:
Ritodrine may interact with the folloing medications:
-Anesthetics: may potentiate the hypotensive effects
-Diazoxide, parenteral
-Magnesium sulfate
-Meperidine
-sympathomimetic amines: may be additive
-Beta-adrenergic antagonists: inhibit Ritodrine
-Corticosteroids: may cause pulmonary edema
Chemical IUPAC Name: 4-[2-[2-hydroxy-2-(4-hydroxyphenyl)-1-methyl-ethyl]aminoethyl]phenol
Chemical Formula: C17H21NO3
Half Life: 1.7-2.6 hours
Drug Type: Approved Drug
# Accession No: APRD00541
CAS Registry Number: 26652-09-5
| | |
